A randomised clinical trial has found that treating pancreatic cancer patients with chemotherapy before surgery significantly improved 1-year survival rates compared to immediate surgery.
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumour cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10 per cent to 30 per cent of treated patients experience long-term improvement. New findings could now bolster the effectiveness of immune-checkpoint therapy.
Missouri [US], October 20 (ANI): After 14 months, there is a 70-80 per cent risk that non-small cell lung cancer, one of the two primary types of lung cancer, would become resistant to the pharmacological therapy that was initially used to treat it. There aren't many existing therapy alternatives if it occurs.
Columbia [US], October 20 (ANI): When a person is diagnosed with non-small cell lung cancer, one of the two primary types of lung cancer, there is a 70-80 per cent risk that cancer will acquire resistance to the initial medication therapy used to treat it after 14 months. If this occurs, there aren't many therapy choices right now. Researchers are on a mission to discover a solution.